ClinicalTrials.gg
TerminatedNCT07330934Updated Oct 27, 2026

A Study to Evaluate Efficacy and Safety of IBI356 in Participants With Moderate to Severe Atopic Dermatitis

A Phase 2 interventional study of Dupilumab and Placebo in Atopic Dermatitis, sponsored by Innovent Biologics (Suzhou) Co. Ltd.. Terminated at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by Innovent Biologics (Suzhou) Co. Ltd. (part of Innovent Biologics, Inc.) · Phase 2, Interventional, and Treatment

Why this study was terminated
Sponsor Decision
Updated Oct 27, 2026Now TerminatedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
18
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 207 studies in Dermatitis, Atopic with a site in China — 65 open to participants now, 83 under way, 29 of them phase 3. Dermatitis, Atopic · China.

Enrollment
185th of 191
18 · median 163
Started
2025
with 33 others
Phase 2
58 of 207
16 open now
Registered
174th of 207
by date

Among the 207 studies in Dermatitis, Atopic with a site in China, this one is the 185th largest by enrollment of the 191 interventional ones that give a count, is one of 34 that started in 2025, is one of 58 in phase 2, and was the 174th registered.

Dermatitis, Atopic

1,596 studies on the registry are indexed under Dermatitis, Atopic; 289 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

65 of the 207 studies in Dermatitis, Atopic with a site in China are open now. Recruiting first, the newest first:

60 more — sign in →

All 65 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 195 Dermatitis, Atopic studies recruiting now, 84 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 52 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 207 studies in Dermatitis, Atopic with a site in China, or all of them as a file.
02

Study summary

This is a multi-center, randomized, double-blind, parallel, placebo-controlled phase 2 clinical study. A total of 403 adult participants with moderate to severe AD are planned to be enrolled to evaluate efficacy, safety, PK characteristics, immunogenicity, and changes in PD characteristics of IBI356.

03

Conditions studied

  • Atopic Dermatitis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Able to understand and sign the form (ICF);
  2. Aged ≥ 18 years, male or female;
  3. Diagnosis of AD for at least 1 year (defined by the American Academy of Dermatology Consensus Criteria);
  4. EASI score of 16 or higher at baseline, vIGA-AD of 3 or 4 at baseline, AD involvement of 10% or more of BSA at baseline, weekly average of daily PP-NRS of ≥ 4 at baseline;
  5. Participants with documented inadequate response to topical medications or for whom topical treatments are otherwise medically inadvisable.

Exclusion criteria

Exclusion Criteria:

  1. Presence of diseases that may affect the safety or efficacy, including but not limited to psychistric disorders, central nervous system, cardiovascular system, digestive system, respiratory system, urinary system, and hematological or metabolic system diseases.
  2. Known history of active tuberculosis or clinically suspected tuberculosis; or chest imaging suggesting evidence of suspected tuberculosis; or any other clinical evidence of latent tuberculosis.
  3. Has known or suspected helminth or other parasitic infection.
  4. History of , except excised or curatively treated localized basal cell carcinoma (BCC) or cutaneous squamous cell carcinoma (cSCC).
  5. History of severe drug allergy or anaphylaxis.
  6. Fainting, hemophobia, or inability to tolerate venipuncture.
  7. Women who are pregnant or breastfeeding, or female participants who have a positive pregnancy test at screening or randomization.
  8. Have received an organ or hematopoietic stem cell transplant.
  9. Positive ; or positive HBcAb with positive HBV-DNA; or positive antibody with positive HCV-RNA; or positive treponema pallidum antibody; or positive serology at screening.
  10. Having received any of the specified therapy within the specified timeframe(s) prior to the baseline visit.

The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    IBI356 dose 4

    Participants receive IBI356 through W16

    Drug: IBI356

  • Experimental
    IBI356 dose 2

    Participants receive IBI356 through W16

    Drug: IBI356

  • Experimental
    Dupilumab

    Participants receive dupilumab through W16

    Drug: Dupilumab

  • Experimental
    IBI356 dose 5

    Participants receive IBI356 through W16

    Drug: IBI356

  • Experimental
    IBI356 dose 1

    Participants receive IBI356 through W16

    Drug: IBI356

  • Placebo comparator
    Placebo

    Participants receive placebo through W16

    Drug: Placebo

  • Experimental
    IBI356 dose 3

    Participants receive IBI356 through W16

    Drug: IBI356

Interventions

  • Dupilumab by subcutaneous injection

  • DrugPlacebo

    Placebo by subcutaneous injection

  • DrugIBI356

    IBI356 by subcutaneous injection

06

What researchers measure

Primary outcomes

  1. Percent change from baseline in Eczema Area and Severity Index (EASI) score

    The EASI is an Investigator-assessed validated tool used to measure the extent (area) and severity of AD. Total score ranges from 0 to 72 with a higher score indicating increased extent and severity of AD.

    Time frame: week 24

Secondary outcomes

  1. Proportion of participants achieving Validated Investigator Global Assessment scale for Atopic Dermatitis (vIGA-AD) of 0 (clear) or 1 (almost clear) with a ≥2-point reduction

    The vIGA-AD is sn investigator-completed assessment scale used to determine severity of AD and clinical response to treatment. It is based on a 5-point scale, ranging from 0 (clear) to 4 (severe).

    Time frame: week 16, 24

  2. Proportion of participants with EASI-75/90/100

    The EASI is an Investigator-assessed validated tool used to measure the extent (area) and severity of AD. Total score ranges from 0 to 72 with a higher score indicating increased extent and severity of AD.

    Time frame: week16, 24

  3. Proportion of participants with a ≥4-point reduction from baseline in the weekly average of the Peak Pruritus-Numerical Rating Scale (PP-NRS)

    The PP-NRS is a validated single item 0-10 numeric rating scale assessing peak pruritus (itch) associated with AD with 0 = no itch and 10 = worst itch imaginable.

    Time frame: week 16, 24

  4. Change in EASI from baseline

    The EASI is an Investigator-assessed validated tool used to measure the extent (area) and severity of AD. Total score ranges from 0 to 72 with a higher score indicating increased extent and severity of AD.

    Time frame: Baseline to Week 48

  5. Change in DLQI from baseline

    The DLQI is a validated 10-item questionnaire to measure dermatology-specific quality of life (QoL) in adult patients. Overall scoring ranges from 0 to 30, with a higher score indicating a poorer QoL.

    Time frame: Baseline to Week 48

  6. Change in POEM from baseline

    The POEM is a 7-item self-assessment questionnaire that assesses disease symptoms on a 5-point scale; 0 (no days) to 4 (every day in the last week). The sum of the 7 items gives the total POEM score of 0 (absent disease) to 28 (very severe). Higher scores indicated more severe disease and poor quality of life.

    Time frame: Baseline to Week 48

  7. Incidences of adverse events (AEs), treatment emergent adverse events (TEAEs), and serious adverse events (SAEs)

    Time frame: Baseline to Week 48

  8. Serum IBI356 concentrations at prespecified timepoints

    Time frame: Baseline to Week 24

  9. Percentage of Participants with Treatment-emergent ADA of IBI356

    Time frame: Baseline to Week 24

  10. Serum IL-13 (PD marker) be assessed as dose-dependent drug responses

    Time frame: Baseline to Week 48

07

Study locations

1 site
  • Peking University People's Hospital
    Beijing, Beijing Municipality 100044, China
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Dec 2025 to primary completion in Aug 2026, 7 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 27, 2026: primary completion Jun 2027 → Aug 2026 and completion Dec 2027 → Aug 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 15, 2025
First posted
Jan 9, 2026
StartActual
Dec 31, 2025
Primary completionActual
Aug 18, 2026was Jun 2027
CompletionActual
Aug 18, 2026was Dec 2027
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Terminated Sponsor Decision
changed Oct 27, 2026
Primary completion
Jun 30, 2027→Aug 18, 2026 (actual)
Oct 27, 2026
Study completion
Dec 31, 2027→Aug 18, 2026 (actual)
Oct 27, 2026
Enrollment
403 (estimated)→18 (actual)
Oct 27, 2026
Show all 1 update
  1. Oct 27, 2026
    Recruiting→Terminated
    Why stopped Sponsor Decision
    Primary completion Jun 30, 2027→Aug 18, 2026 (now actual)
    Study completion Dec 31, 2027→Aug 18, 2026 (now actual)
    Enrollment 403 (estimated)→18 (actual)
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07330934
Responsible party
Sponsor
First posted
Jan 9, 2026
Start date
Dec 31, 2025
Primary completion
Aug 18, 2026
Completion
Aug 18, 2026
Last update
Oct 27, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion